Objective: To determine the effect of two doses of prostaglandin E1 (PGE1, alprostadil) combined with unfractionated heparin on the hemofilter life-span and the coagulation profile during continuous venovenous hemofiltration.
Design: Prospective, randomized, controlled trial.
Setting: Intensive care unit at a university-affiliated hospital.
Patients: Twenty-four critically ill, mechanically ventilated patients with postoperative acute renal failure who require continuous venovenous hemofiltration.
Interventions: The patients were anticoagulated with 5 ng/kg/min PGE1 and 6 IU/kg/hr heparin or 20 ng/kg/min PGE1 and 6 IU/kg/hr heparin, injected into the extracorporeal circuit before the hemofilter.
Measurements And Main Results: The life-span of 43 hemofilters was evaluated. They were used until extracorporeal line pressure exceeded 250 mm Hg, ultrafiltration rate decreased to 16 mL/min, or grossly visible extracorporeal clotting occurred. Blood was sampled from the afferent (prefilter) and efferent (postfilter) lines of the extracorporeal circuit. Platelet counts, in vitro platelet function, plasma concentrations of platelet factor 4, prothrombin fragment F1+2, thrombin-antithrombin complex, routine plasma coagulation tests, and hemodynamic profile were determined before and during hemofiltration. Hemofilter usage was significantly longer in patients anticoagulated with 20 ng/kg/min PGE1 (32 +/- 3 [SEM] hrs) than with 5 ng/kg/min PGE1 (22 +/- 3 hrs). In vitro bleeding parameters were significantly prolonged in postfilter blood in patients receiving 20 ng/kg/min PGE1. Prefilter, there was no antiplatelet activity in either group and platelet counts remained stable. No intra- or intergroup differences in plasma coagulation profile or hemodynamic parameters were detected.
Conclusion: Extracorporeal administration of PGE1, combined with low-dose heparinization, inhibits platelet reactivity and preserves hemofilter life dose-dependently.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00003246-199807000-00021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Add-On Prostaglandin E in Venovenous Extracorporeal Membrane Oxygenation: A Randomized, Double-Blind, Placebo-controlled Pilot Trial.
Am J Respir Crit Care Med
July 2022
Department of Medicine I.
Prostaglandin E (alprostadil; PGE), in addition to low-dose unfractionated heparin, increases the biocompatibility of extracorporeal systems and enhances the efficacy of artificial organs without increasing bleeding risk. We investigated the safety and efficacy of PGE in adults receiving venovenous extracorporeal membrane oxygenation (ECMO). This study was a randomized, double-blind, placebo-controlled phase II pilot trial at two medical intensive care units at the Medical University of Vienna, Austria.
View Article and Find Full Text PDFInhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials.
Trials
December 2014
Department of Pediatrics, Children's Hospital of Michigan, 3901 Beaubien Blvd., 4H42, Detroit, MI, 48201, USA.
Background: Inhaled nitric oxide (INO), a selective pulmonary vasodilator, has revolutionized the treatment of neonatal hypoxemic respiratory failure (NHRF). However, there is lack of sustained improvement in 30 to 46% of infants. Aerosolized prostaglandins I2 (PGI2) and E1 (PGE1) have been reported to be effective selective pulmonary vasodilators.
View Article and Find Full Text PDFPrevention of contrast-induced nephropathy with prostaglandin E1 in high-risk patients undergoing percutaneous coronary intervention.
Int Urol Nephrol
April 2014
Department of Cardiology, Affiliated Hospital of XuZhou Medical College, No. 99 Huaihai West Road, Xuzhou, 221002, China,
Purpose: Contrast-induced nephropathy (CIN) is an important complication in the use of iodinated contrast media. The present study aimed to assess the safety and efficacy of prostaglandin E1 (PGE1) in prevention of CIN in patients with high-risk factors undergoing percutaneous coronary intervention (PCI).
Methods: The study group consisted of 163 patients who had undergone a coronary intervention procedure between January 1, 2012 and October 31, 2012.
Effect of prostaglandin E1 inhalation on pulmonary hypertension following corrective surgery for congenital heart disease.
Exp Clin Cardiol
December 2013
Department of Cardiac Surgery, Charles Sturt University, Wagga Wagga, New South Wales, Australia;
Background: Intravenous infusion of prostaglandin E1 (PGE1) has been used to treat pulmonary arterial hypertension (PAH); however, the efficacy and safety of inhaled PGE1 is unclear.
Objectives: To investigate the effect of inhaled PGE1 on PAH following corrective surgery for congenital heart disease.
Methods: Sixty patients with postoperative residual PAH following corrective surgery for congenital heart disease were randomly assigned to a control group, a PGE1 infusion group (intravenous PGE1 infusion; 30 ng/kg/min daily for 10 days) or a PGE1 inhalation group (100 μg nebulized PGE1 every 8 h for 10 days).
Prostaglandin E1 increases the blood flow rate of saphenous vein grafts in patients undergoing off-pump coronary artery bypass grafting.
J Cardiothorac Vasc Anesth
December 2013
Department of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Objective: To compare the effects of prostaglandin E1 (PGEl) versus placebo on blood flow rate in coronary artery bypass grafts.
Design: A prospective, randomized, double-blinded study.
Setting: A teaching hospital.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!